of today's call. We have again asked investors and shareholders to submit their questions in advance, and we would like to thank all of you who did. Question number one, can you comment on additional acquisitions in the pharmacy space? Are you looking beyond Florida? How would you fund future acquisitions? Would you have to dilute current shareholders? At this point in time, we see many advantages to concentrating a brick-and-mortar focus on Florida. due to attractive population demographics and our well-established infrastructure. We are actively exploring additional acquisitions in Florida, looking for transactions which meet our specific requirements, namely in markets not saturated by the larger chains, established locations with solid customer bases, and importantly, attractive financials, specifically profitable operations. To be clear, we are approaching future action decisions in a very conservative and prudent manner, specifically as it relates to their ability to add equitably to our business, their margins, cash flow and profitability. Because of our improved operating results, we have significant flexibility on how we could fund a transaction. We could consider using a combination of restricted shares, earn outs, cash or even bank lines of credit, which would allow us to capture value without simply diluting our shareholders. Question number two, Will AI play a role in the company's operations? If so, how will it affect the company's business? AI is becoming increasingly important to our growth strategy and operating capabilities. It enables us to identify and respond to trends across our e-commerce and healthcare businesses more quickly, while also helping us efficiently process and analyze the growing volumes of patient data generated as our healthcare operations expand. And AI is also a core component of ClearMetrics 4, our proprietary healthcare data analytics and reporting platform, which was recently deployed internally and with customers. On the e-commerce side, we have developed several new systems internally, which alternate tasks and improve efficiency using AI. Question number three, does the company have any update on the status of the ongoing lawsuit? as of today there is no update beyond what we have already disclosed in our previously filed periodic reports our form 10q for the second quarter will be filed shortly and contains our current disclosure on this matter so i'd refer you to there and to our prior filings this remains in the hands of council and our insurance company we remain committed to resolving it as quickly as possible while protecting the long-term interests of our shareholders that was the final question that we received from investors. Thank you all again for submitting them. Please remember that you can submit your questions on our Investor Relations email, which is investors at nextplat.com, or with our IR contact listed on our press releases, Michael Glickman at mike at mwgco.net. That concludes our earnings conference call. We look forward to continuing to share with you our progress in the weeks and months ahead. Have a nice rest of your day.
